RPG Life Sciences Expands Global Reach, Reports Steady Q1 Growth Jul 25, 2025
RPG Life Sciences Reports Q1 FY26 Results, Appoints New API Business Chief Jul 25, 2025
More news about RPG Life Sciences
25Jul 25
RPG Life Sciences Reports 2.1% Revenue Growth in Q1 FY26, Maintains Strong EBITDA Margin
RPG Life Sciences Limited announced its Q1 FY26 financial results, showing a 2.1% year-on-year revenue increase to Rs. 168.90 crores. The company maintained a strong EBITDA margin of 24.1%. Domestic Formulations grew by 9.5%, while International Formulations and APIs declined. The company is focusing on inorganic growth, manufacturing capacity expansion, portfolio growth, and digital initiatives. Mr. Deepak Shukla was appointed as Chief Executive - API Business.
29Apr 25
RPG Life Sciences Reports Stellar Q4 FY25 Results: PAT Soars 786%, Announces Special Dividend
RPG Life Sciences Limited announced impressive financial results for Q4 and FY 2024-25. Q4 highlights include a 13% YoY revenue increase to ₹143.09 crore, 41% PBT growth, and a remarkable 786% PAT jump to ₹117.35 crore. Full-year results show 12% revenue growth to ₹653.43 crore and 28% PBT increase. The company reported exceptional items, including a ₹98.93 crore profit from land assignment and a ₹16.33 crore loss from a fire incident. A final dividend of ₹20 and special dividend of ₹4 per share were recommended. The company maintains a strong cash position of ₹266 crore and is exploring inorganic growth opportunities.
28Apr 25
RPG Life Sciences Reports Stellar Q4 Results, Declares Special Dividend Amid Leadership Changes
RPG Life Sciences announced impressive Q4 FY2025 results with net profit soaring to ₹1,173.50 crore, up from ₹132.40 crore in Q4 FY2024. Revenue increased to ₹1,430.90 crore. The company declared a final dividend of ₹20 and a special dividend of ₹4 per equity share. Exceptional items included a ₹1,262.30 crore profit from land assignment and a ₹163.30 crore loss from a fire incident. Key leadership changes were announced, including the appointment of a new Managing Director.